IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. The company provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. It also offers diagnostic and health-monitoring products for livestock, poultry, and dairy markets; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:IDXX
CUSIP45168D10
Phone207-556-0300
Debt
Debt-to-Equity Ratio-14.77
Current Ratio0.96
Quick Ratio0.73
Price-To-Earnings
Trailing P/E Ratio69.66
Forward P/E Ratio54.66
P/E Growth2.28
Sales & Book Value
Annual Sales$1.97 billion
Price / Sales10.05
Cash Flow$3.9593 per share
Price / Cash57.71
Book Value($0.62) per share
Price / Book-368.53
Profitability
EPS (Most Recent Fiscal Year)$3.28
Net Income$263.14 million
Net Margins14.50%
Return on Equity-703.80%
Return on Assets21.21%
Miscellaneous
Employees8,000
Outstanding Shares86,590,000
Market Cap$21.62 billion
IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions
What is IDEXX Laboratories' stock symbol?
IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."
How will IDEXX Laboratories' stock buyback program work?
IDEXX Laboratories announced that its Board of Directors has initiated a stock repurchase plan on Sunday, June 4th 2017, which allows the company to buyback 3,000,000 shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Stock buyback plans are usually a sign that the company's management believes its stock is undervalued.
How were IDEXX Laboratories' earnings last quarter?
IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted its earnings results on Wednesday, August, 1st. The company reported $1.23 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.17 by $0.06. The firm earned $580.75 million during the quarter, compared to analyst estimates of $574.68 million. IDEXX Laboratories had a negative return on equity of 703.80% and a net margin of 14.50%. The firm's revenue was up 14.1% on a year-over-year basis. During the same quarter last year, the business posted $0.87 EPS. View IDEXX Laboratories' Earnings History.
When is IDEXX Laboratories' next earnings date?
How can I listen to IDEXX Laboratories' earnings call?
IDEXX Laboratories will be holding an earnings conference call on Thursday, November 1st at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8002301766.
What guidance has IDEXX Laboratories issued on next quarter's earnings?
IDEXX Laboratories issued an update on its FY18 earnings guidance on Wednesday, August, 1st. The company provided EPS guidance of $4.10-4.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.15. The company issued revenue guidance of $2.205-2.23 billion, compared to the consensus revenue estimate of $2.23 billion.
What price target have analysts set for IDXX?
6 Wall Street analysts have issued 12-month price objectives for IDEXX Laboratories' stock. Their forecasts range from $215.00 to $260.00. On average, they anticipate IDEXX Laboratories' share price to reach $238.00 in the next year. This suggests a possible upside of 4.2% from the stock's current price. View Analyst Price Targets for IDEXX Laboratories.
What is the consensus analysts' recommendation for IDEXX Laboratories?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEXX Laboratories.
Who are some of IDEXX Laboratories' key competitors?
Some companies that are related to IDEXX Laboratories include IPSEN S A/S (IPSEY), Immunomedics (IMMU), Neogen (NEOG), Myriad Genetics (MYGN), Quidel (QDEL), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Vermillion (VRML) and Riot Blockchain (RIOT).
Who are IDEXX Laboratories' key executives?
IDEXX Laboratories' management team includes the folowing people:
- Mr. Jonathan W. Ayers, Chairman, CEO & Pres (Age 62)
- Mr. Brian P. McKeon, CFO, Exec. VP & Treasurer (Age 56)
- Ms. Jacqueline L. Studer, Corp. VP, Gen. Counsel & Sec. (Age 59)
- Mr. Giovani Twigge, Chief HR Officer & Corp. VP (Age 54)
- Mr. Jay Mazelsky, Exec. VP (Age 57)
Who are IDEXX Laboratories' major shareholders?
IDEXX Laboratories' stock is owned by many different of retail and institutional investors. Top institutional shareholders include MERIAN GLOBAL INVESTORS UK Ltd (1.04%), Bank of Montreal Can (0.21%), Welch & Forbes LLC (0.21%), Davis R M Inc. (0.18%), Rathbone Brothers plc (0.12%) and Nisa Investment Advisors LLC (0.08%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Lawrence D Kingsley, Michael Lane, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for IDEXX Laboratories.
Which institutional investors are selling IDEXX Laboratories stock?
IDXX stock was sold by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Spence Asset Management, Davis R M Inc., Franklin Street Advisors Inc. NC, Welch & Forbes LLC, Woodstock Corp, KAMES CAPITAL plc and Taylor Frigon Capital Management LLC. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Michael Lane and William T End. View Insider Buying and Selling for IDEXX Laboratories.
Which institutional investors are buying IDEXX Laboratories stock?
IDXX stock was acquired by a variety of institutional investors in the last quarter, including Rathbone Brothers plc, Bank of Montreal Can, DNB Asset Management AS, EFG Asset Management Americas Corp., Pittenger & Anderson Inc., Nisa Investment Advisors LLC, Lourd Capital LLC and Kovack Advisors Inc.. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.
How do I buy shares of IDEXX Laboratories?
Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IDEXX Laboratories' stock price today?
One share of IDXX stock can currently be purchased for approximately $228.49.
How big of a company is IDEXX Laboratories?
IDEXX Laboratories has a market capitalization of $21.62 billion and generates $1.97 billion in revenue each year. The company earns $263.14 million in net income (profit) each year or $3.28 on an earnings per share basis. IDEXX Laboratories employs 8,000 workers across the globe.
What is IDEXX Laboratories' official website?
How can I contact IDEXX Laboratories?
IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]
MarketBeat Community Rating for IDEXX Laboratories (NASDAQ IDXX)
MarketBeat's community ratings are surveys of what our community members think about IDEXX Laboratories and other stocks. Vote "Outperform" if you believe IDXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
